

Aiming to Become a Top Japanese Pharmaceutical Company

- Review of 2010 and Plans for 2011 -

CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama

February 2/3, 2011



Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.



2010 Full Year Results

Growth of mainstay products compensate NHI price cut Operating income drops due to low Tamiflu demand

(billions of yen)	2009	2010	YoY	vs. plan
Revenues	428.9	379.5	-11.5%	-4.1%
Sales (excl. Tamiflu)	342.9	357.4	+4.2%	-0.1%
Domestic sales (excl. Tam	324.4	+4.9%	-0.1%	
Operating income	82.6	66.2	-19.9%	-5.4%
% revenues	19.3%	17.4%		
Net income	56.6	41.4	-26.9%	-3.7%
% revenues	13.2%	10.9%		



Review of 2010

- Domestic sales excluding Tamiflu: +4.9%
- Launch of Actemra in US
- Approval of Epogin in predeposit of autologous blood transfusion
- Completion of All Patients Surveillance : Actemra & Avastin
- NDA filing of 2 projects/4 products



Smooth progress in both Sales & R&D


Aiming to Become a Top Japanese Pharmaceutical Company


- Review of 2010 and Plans for 2011 -



Domestic Sales excluding Tamiflu

Increased presence in Oncology and Bone & Joint









Progress in R&D (1)

< Proof of Concept confirmed >










< In-house projects entering clinical trials >





SA237 Rheumatoid Arthritis Humanized anti-human IL-6 receptor monoclonal antibody



2011 Forecast

Sales & profits to grow from new product launches and penetration of existing products

(billions of yen)	2010	2011 plan	YoY
Revenues	379.5	403.0	+6.2%
Sales excluding Tamiflu	357.4	379.5	+6.2%
SG&A	96.2	101.0	+5.0%
% of revenues	25.3%	25.1%	
R&D	54.7	59.2	+8.2%
% of revenues	14.4%	14.7%	
Operating income	66.2	75.0	+13.3%
% of revenues	17.4%	18.6%	
Net income	41.4	42.5	+2.7%
% of revenues	10.9%	10.5%	


Aiming to Become a Top Japanese Pharmaceutical Company

- Review of 2010 and Plans for 2011 -



Towards a Top Pharmaceutical Company

Aiming to become a top pharmaceutical company through the achievement of Sunrise 2012





FY2010 Consolidated Financial Overview

CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President and CFO Yoshio Itaya

February 2,3 2011



Summary

- Revenues and Profits declined due to Tamiflu low demand
 - Revenues 379.5 billion JPY (-11.5%)
 - Operating Income 66.2 billion JPY (-19.9%)
 - Sales of Tamiflu -58.0 billion JPY (-76.1%)
- Solid growth in business excluding Tamiflu
 - Sales excluding Tamiflu increased by 14.5 billion JPY (+4.2%)
 - Domestic sales grew by 4.9% with double digit growth in oncology despite negative impact from NHI price revision
 - Overseas sales slightly declined due to strong Yen (-1.8%)
 - Operating income excluding Tamiflu also increased
 - Year-end dividend 23 JPY per share (40 JPY annual dividend), achieving a payout ratio of 52.5%
 - +6 JPY from the original forecast, matching last year's total dividends including special dividends



Financial Overview Jan-Dec


(Billion JPY)	2009 Jan-Dec	As % of Revenues	2010 Jan-Dec	As % of Revenues	Variance	%	(Billion JPY)
Revenues	428.9		379.5		-49.4	-11.5	Sales excl. Tamiflu +14.5
Sales	419.1		375.6		-43.5	-10.4	Sales of Tamiflu* -58.0
excl. Tamiflu	342.9		357.4		+14.5	+4.2	Other Operating Revenues
Tamiflu	76.2		18.2		-58.0	-76.1	-5.9
Other Operating Revenues	9.8		3.9		-5.9	-60.2	Decrease in milestone income
Operating Income	82.6	19.3	66.2	17.4	-16.4	-19.9	
Non-operating Income	9.4		2.4		-7.0	-74.5	➢ Operating Income -16.4
Non-operating Expenses	1.6		3.5		+1.9	+118.8	➢ Non-operating Inc./Exp8.9
Recurring Profit	90.4	21.1	65.1	17.2	-25.3	-28.0	Extraordinary Inc./Exp. +1.6
Extraordinary Gain	0.3		0.6		+0.3	+100.0	
Extraordinary Loss	1.3		0.0		-1.3	-100.0	
Net Income	56.6	13.2	41.4	10.9	-15.2	-26.9	


Average ex	xchange rate (JPY)		*Tamiflu (Billion JPY)			
	2009 Jan-Dec	2010 Jan-Dec		2009 Jan-Dec	2010 Jan-Dec	Variance
CHF	86.20	84.17	Ordinary	36.2	1.6	-34.6
EUR	130.10	116.32	Govt. Stockpile etc.	40.0	16.6	-23.4

FY2010 Consolidated Financial Overview



Sales excluding Tamiflu Jan-Dec







Tamiflu Sales Performance

								Fiscal Term	Sales]	
(E	Billion JPY)	FY2	005.12	FY20	06.12	FY20	07.12	FY20	08.12	FY20	09.12	FY20	10.12	FY20	FY2011.12		€ases sentin
	1	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Sales	(millio
	2004-05	23.2														24.6	1.4
	2005-06		11.9	9.9												21.8	0.9
	2006-07				3.7	5.0										8.7	1.0
Ordinary	2007-08						5.2	1.4								6.6	0.6
Ordinary	2008-09								5.7	11.0						16.7	1.2
	2009-10										25.2	1.4				26.6	2.0
	2010-11												0.2	5.3		5.5	-
	2011-12														2.5		
	Ordinary	35.1	(+26.5)	13.6	(-21.5)	10.2	(-3.4)	7.1	(-3.1)	36.2	(+29.1)	1.6	(-34.6)	7.8	(+6.2)		
	2005-06		0.2	6.5												6.7	1
	2006-07				17.9	18.9										36.8	-
Govt.	2007-08						9.6	0.2								9.8	
Stockpile	2008-09								1.1	14.4						15.5	
etc.	2009-10										25.6	10.6				36.2	-
	2010-11												5.9	0.4		6.3	
	2011-12														4.0		
	Govt. Stockpile etc.	0.2	(+0.2)	24.4	(+24.2)	28.5	(+4.1)	1.3	(-27.2)	40.0	(+38.7)	16.6	(-23.4)	4.4	(-12.2)		4
		23.2	12.0	16.3	21.6	23.8	14.8	1.6	6.8	25.4	50.8	12.0	6.1	5.7	6.5	1	
	Total	35.2	(+26.6)	38.0	(+2.8)	38.7	(+0.7)	8.4	(-30.3)	76.2	(+67.8)	18.2	(-58.0)	12.2	(-6.0)		



Company forecast

*Total patients number of the controlled samples in the infectious Diseases Weekly Report, period between late October and mid-April (between early July 2009 and mid-March 2010 for 2009-10), published by Japan's National Institute of Infectious Diseases.

Jan-Dec


2009



Operating Income Jan-Dec

Jan-Dec

2010



(Billion JPY)	2009	2010	Variance	
(Billion 3FT)	Jan-Dec	Jan-Dec	Variance	(%)
Revenues	428.9	379.5	-49.4	-11.5
Cost of Sales	192.9	162.4	-30.5	-15.8
Gross Profit	236.1	217.1	-19.0	-8.0
Sales	226.3	213.1	-13.2	-5.8
Other Operating Revenues	9.8	3.9	-5.9	-60.2
SG&A (excl. R&D) exp.	98.2	96.2	-2.0	-2.0
R&D exp.	55.3	54.7	-0.6	-1.1
Operating Income	82.6	66.2	-16.4	-19.9

- Decrease in Gross Profit -13.2
 Decrease in Tamiflu sales
- Decrease in Other Operating Revenues -5.9
 Decrease in milestone income
- Decrease in SG&A (excl. R&D) exp. +2.0
- Decrease in R&D exp. +0.6

15



Financial Overview Oct-Dec

(Dillion IDV)	2009		2010		Variance			(Billion JPY)
(Billion JPY)	Oct-Dec	As % of Revenues	Oct-Dec	As % of Revenues	wanance %			
Revenues	119.2		103.4		-15.8	-13.3	Sales excl. Tamiflu	+4.7
Sales	115.7		102.3		-13.4	-11.6	Avastin	+5.2
excl. Tamiflu	95.3		100.0		+4.7	+4.9	Actemra (Domestic)	+2.0
Tamiflu	20.4		2.3		-18.1	-88.7	Rituxan	+1.0
Other Operating Revenues	3.6		1.1		-2.5	-69.4	Tarceva	+0.7
Cost of sales	49.5		42.8		-6.7	-13.5	Xeloda	+0.7
							Actemra (Overseas)	-1.6
Gross Profit	69.7	58.5	60.6	58.6	-9.1	-13.1	Neutrogin (Overseas)	-1.5
SG&A (excl. R&D) exp.	28.3		24.7		-3.6	-12.7	Epogin	-1.3
R&D exp.	17.5		14.8		-2.7	-15.4	Sales of Tamiflu*	-18.1
Operating Income	23.8	20.0	21.1	20.4	-2.7	-11.3	Other Operating Rev	venues -2.5
Recurring Profit	24.4	20.5	20.8	20.1	-3.6	-14.8		
Net Income	15.7	13.2	13.4	13.0	-2.3	-14.6	Decrease in milestone	income
							Operating Income	-2.7

* Tamiflu (Billion JPY)	2009 Oct-Dec	2010 Oct-Dec	Variance	
Ordinary	17.7	0.2	-17.5	
Govt. Stockpile etc.	2.7	2.1	-0.6	




Financial Overview Jan - Dec


	Revised Fo Oct. 2		Actua	al	Varia	200	(Bill	ion JPY)
(Billion JPY)	2010 Jan-Dec	As %of Revenues	2010 Jan-Dec	As % of Revenues	Achiev.			0.4
Revenues	395.8		379.5		-16.3	<u>(%)</u> 95.9	Sales excl. Tamiflu	-0.4
Sales	390.8		375.6		-15.2	96.1	Avastin Herceptin	+1.4 +0.6
excl. Tamiflu	357.8		357.4		-0.4	99.9		+0.6
Tamiflu	33.0		18.2		-14.8	55.2	Rituxan	+0.5
							Epogin	-1.2
Other Operating Revenues	5.0		3.9		-1.1	78.0	Actemra (Domestic)	-1.0
Cost of sales	170.8		162.4		-8.4	95.1		
Gross Profit	225.0	56.8	217.1	57.2	-7.9	96.5	Sales of Tamiflu	-14.8
SG&A (excl. R&D) exp.	100.0		96.2		-3.8	96.2	Operating Income	-3.8
R&D exp.	55.0		54.7		-0.3	99.5		0.0
Operating Income	70.0	17.7	66.2	17.4	-3.8	94.6		
Recurring Profit	68.7	17.4	65.1	17.2	-3.6	94.8		
Net Income	43.0	10.9	41.4	10.9	-1.6	96.3		

FY2010 Consolidated Financial Overview



Sales excluding Tamiflu Jan-Dec








Balance Sheet Items (Assets)

(Billion JPY)




- Cash and deposits -30.8
- Marketable securities +7.5
- > Accounts receivable -8.2
- Inventories +12.3


Decrease in Tamiflu (ordinary) sales 2009 Oct-Dec: 17.7 2010 Oct-Dec: 0.2



Balance Sheet Items (Liabilities)

(Billion JPY)





- Accounts payable -14.8
 Decrease in purchase Tamiflu Manufacturing site change
- Accrued income taxes -18.4
- ➤ Others -14.0

Decrease in accrued expenses and accrued consumption taxes

Equity Ratio		
Dec. 2009	Dec. 2010	Variance
80.0%	88.0%	+8.0%pts


Actual 2010

FY2010 Consolidated Financial Overview



Cash Flow Statement Jan - Dec

(Billion JPY)



Cash flow from operating activities	+15.6
Income before taxes and minority interes	ts +65.7
Depreciation and amortization	+18.0
Increase in working capital	-19.5
Decrease in notes and accounts receivable	+7.9
Increase in inventories	-12.7
Decrease in notes and accounts payable	-14.7
Income taxes paid	-38.9
Cash flow from investing activities	-20.2
Increase in time deposits	-0.9
Increase in marketable and investment se	ecurities
	-5.9
Purchases of fixed assets	-13.6
Cash flow from financing activities	-23.1
Payment of dividends	-21.8



2011 Forecast Jan - Dec

	Actua	al	Foreca	ast	Varia				
(Billion JPY)	2010		2011		Variai		(Billion JPY)		
	Jan-Dec	As %of Revenues	Jan-Dec	As % of Revenues		%	➤ Sales excl. Tamiflu +22.1		
Revenues	379.5		403.0		+23.5	+6.2	➤ Sales of Tamiflu -6.0		
Sales	375.6		391.7		+16.1	+4.3			
excl. Tamiflu	357.4		379.5		+22.1	+6.2	+7.4		
Tamiflu	18.2		12.2		-6.0	-33.0	increase in milestone income increase in income related to Actemra		
Other Operating Revenues	3.9		11.3		+7.4	+189.7	➢ Operating Income +8.8		
Cost of sales	162.4		167.8		+5.4	+3.3			
Gross Profit	217.1	57.2	235.2	58.4	+18.1	+8.3	Non-operating Inc./Exp. +1.6		
SG&A (excl. R&D) exp.	96.2		101.0		+4.8	+5.0			
R&D exp.	54.7		59.2		+4.5	+8.2			
Operating Income	66.2	17.4	75.0	18.6	+8.8	+13.3			
Recurring Profit	65.1	17.2	75.5	18.7	+10.4	+16.0			
Net Income	41.4	10.9	42.5	10.5	+1.1	+2.7			

Exchange rate (JPY)

		Assumption
	2010 Jan-Dec	2011 Jan-Dec
CHF	84.17	85.00
EUR	116.32	110.00


FX sensitivity Estimated impact of a 1-yen appreciation CHF: +0.3 billion JPY EUR: -0.1 billion JPY on Operation

on Operating Income forecast

FY2010 Consolidated Financial Overview



Sales excluding Tamiflu Jan-Dec






Dividend Policy

> Policy

Aiming to ensure stable profit for all shareholders and a consolidated dividend payout ratio of **over 40% on average**, taking account of strategic funding needs and earnings prospects.



2004 2005 2006 2007 2008 2009 2010 2011



Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President Head of Lifecycle Management & Marketing Unit Yutaka Tanaka

February 2/3, 2011



Projects under Development (as of Feb. 2011)

	Phase I	Phase II	Phase III	Filed
Oncology	CIF/RG7167 - solid tumors CKI27/RG7304 - solid tumors GC33 - liver cancer ★ PA799 - solid tumors ★ GA101/RG7159 - NHL	MRA/Actemra - PC TP300 - GC AF802 - NSCLC WT4869 - myelodysplastic syndromes★ RG435/Avastin - glioblastoma (relapsed) RG1415/Tarceva - NSCLC(1 st line) RG3502(T-DM1) - BC	RG435/Avastin - GC - aBC - glioblastoma RG1273/pertuzumab - BC	EPOCH/Epogin - CIA RG435/Avastin - BC RG1415/Tarceva – PC RG340/Xeloda - GC RG597/Herceptin - GC
Bone & Joint	SA237 - rheumatoid arthritis ★	RG484/Bonviva(oral) - osteoporosis	MRA/Actemra (overseas) - RA(sc) RG484/Bonviva(inj) - osteoporosis	MRA/Actemra (overseas) - sJIA★
Renal				RG744/Mircera - renal anemia
Others	RG1450 - alzheimer's disease	RG1583/taspoglutide - diabetes	CSG452/RG7201 - diabetes★ RG1678/(GLYT1) -schizophrenia★	RG442/Pegasys - HBV★ RG442+RG964/Pegasys + Copegus – cirrhosis★

Letters in orange in-house projects

★: Projects with advances in stages since Oct. 22, 2010



Development Status - Oncology



GC33: Liver cancer

- P1 started in Oct. 2010 in Japan
- Licensed out to Roche in Jan. 2011



WT4869 (WT1 peptide cancer vaccine): Myelodysplastic syndromes P1/2 will start in Feb. 2011

*Co-developed with Dainippon Sumitomo Pharma



Avastin: Colon cancer (adjuvant)

Development suspended

• Did not meet the primary endpoint in P3 study





Development Status - Bone & Joint



Edirol (ED-71): Osteoporosis Approved in Jan. 2011



SA237: Rheumatoid Arthritis P1 started in Dec. 2010

Development Status –



Transplant, Immunology, Infectious diseases and others



tofogliflozin (CSG452): Type 2 diabetes

P3 started in Nov. 2010 in Japan



Pegasys/Copegus: Compensated liver cirrhosis caused by hepatitis C virus

Filed in Oct. 2010 and designated as priority review subject on Jan. 2011



Pegasys: Hepatitis B Filed in Jan. 2011



GLYT1 (RG1678): Schizophrenia

Started P3 multi national study in Jan. 2011



NA808: Hepatitis C


Development suspended

Did not meet the efficacy criteria to proceed



Projected Submissions (Post PoC products and NMEs)

Filings planned each year





GC33 Mode of Action

- Glypican-3 (GPC) is a member of the heparan sulfate proteoglycan families, which is linked to the cell surface through a GPI anchor
- The expression of GPC3 up-regulated especially in hepatocellular carcinoma (HCC)

□ GPC3 is found highly expressed in 70-80% of HCC samples


□ Incidence rate : Approx. 40,000 patients/year in Japan

- GC33 induces antibody-dependent cellular cytotoxicity (ADCC) and elicites antitumor activity in an antigendependent manner
- Currently in phase I (Japan & overseas)



GC33 & Companion Diagnostics

Promotion of personalized healthcare by discovery of biomarkers and the simultaneous development of immunohistochemistry based diagnostics with Roche (Ventana Medical Systems)



Immunohistochemistry utilizing anti-GPC3 antibody



HE stain



About SA237


- Interleukin-6 (IL-6) is produced by various cell types, including lymphocytes or macrophages, and exerts various physiological functions such as proliferation and differentiation of cells.
- Tocilizumab (Actemra) is a monoclonal antibody (MAB) against human IL-6 receptor which blocks the binding of IL-6 to its receptor and inhibits the actions of IL-6.
- Tocilizumab is shown to be effective in the treatment of rheumatoid arthritis.
- SA237 is a follow-on MAB created by applying Chugai's unique antibody engineering technology to tocilizumab.
- SA237 is expected to maintain similar efficacy and safety profile to that of tocilizumab while improving the pharmacokinetic properties, which may provide the benefits of increased convenience.




SA237 Mode of Action

The antibody engineering technology utilized in SA237 has been highly appraised and was accepted by Nature Biotechnology
The antibody engineering

> Improved blood kinetics (animal model) SA237 vs tocilizumab



The antibody engineering technology utilized in SA237; enabling single antibody molecule to bind the target antigen multiple times





Actemra Overseas Development Status

Clinical development conducted by Roche

□ 4 RA related programs

	Study	Details	
New Evidence	FUNCTION	Patient population: Early RA	
	ADACTA	Head-to-head study with Humira	
P3 study	SUMMACTA	Subcutaneous Actemra and intravenous Actemra	
	BREVACTA	Subcutaneous Actemra and placebo	

□ 3 non-RA programs

Indication	Study	Details
sJIA	TENDER	Submitted in Oct. 2010 to FDA/EMA Granted accelerated review by FDA/EMA
Ankylosing Spondylitis	BUILDER 1	Patient population: TNF-naïve
	BUILDER 2	Patient population: TNF-IR



Current Situation of the Requests Made by MHLW Unapproved Drug Committee

MHLW Unapproved Drug Committee

Requested drug manufacturers to develop unapproved drugs with high clinical needs, including 8 cases with 10 indications for Chugai

Date for request	Product	indication	Development status
May 21, 2010	Xeloda	Advanced or recurrent gastric cancer	Filed
	Tarceva	Advanced or recurrent pancreatic cancer	Filed
	Avastin	Advanced or recurrent breast cancer	Filed
	pulmozyme	Cystic fibrosis	Planning
Dec 13, 2010	Avastin	Ovarian cancer	Submitted appeal for "New Drug Application Based on Evidence in the Public Domain"
	Herceptin	Q3W dosage HER2+ metastatic breast cancer	
	Herceptin	HER2 + neo-adjuvant breast cancer	
	Kytril	Radiation	
	Cellcept	Child kidney transplant	
	Bactramin	Prevention & treatment of pneumocystis pneumonia	

Contacts: Corporate Communications Dept.

Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp

Hitoshi Aikawa, Shinichi Hirose, Hiroshi Araki, Kae Miyata

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: ir@chugai-pharm.co.jp

Mac Uchida, Yumiko Watanabe, Yusuke Tokita, Chisato Kitamura